Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
5
83%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

NCT03231124
completedphase_1

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

NCT03812198
completedphase_1

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

NCT03126578
completedphase_2

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

NCT02888236
terminatedphase_1

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

NCT02753218
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03231124Phase 1

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Completed
NCT03812198Phase 1

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Completed
NCT03126578Phase 1

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

Completed
NCT02888236Phase 2

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Completed
NCT02753218Phase 1

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Terminated
NCT01310049Phase 1

LEO 32731 - A Study in Healthy Male Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6